Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research report issued on Tuesday. They presently have a $66.00 target price on the stock. Wedbush’s price objective would suggest a potential upside of 18.43% from the stock’s previous close.

A number of other brokerages also recently issued reports on SRPT. Oppenheimer Holdings Inc. lifted their price target on Sarepta Therapeutics from $60.00 to $76.00 in a research report on Monday. JMP Securities upgraded Sarepta Therapeutics to an “outperform” rating and boosted their target price for the stock from $10.00 to $60.00 in a research report on Monday. Cowen and Company upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $64.00 target price for the company in a research report on Tuesday. SunTrust Banks Inc. upgraded Sarepta Therapeutics from a “reduce” rating to a “neutral” rating in a research report on Wednesday, September 14th. Finally, Jefferies Group restated an “underperform” rating and issued a $7.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus price target of $51.01.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 13.87% during mid-day trading on Tuesday, hitting $55.73. 21,126,825 shares of the stock traded hands. The firm’s 50-day moving average is $28.17 and its 200-day moving average is $21.37. The stock’s market cap is $2.67 billion. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $56.80.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-wedbush-2.html

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company posted ($0.87) earnings per share. On average, analysts forecast that Sarepta Therapeutics will post ($4.98) earnings per share for the current year.

In other news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at $2,309,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the last quarter. State Street Corp boosted its stake in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at $13,506,000. 72.09% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.